Moteur de recherche d’entreprises européennes
Financement de l’UE (4 725 090 €) : Stratégies de guérison des infections associées aux implants et d’amélioration de la longévité des dispositifs Hor04/07/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Stratégies de guérison des infections associées aux implants et d’amélioration de la longévité des dispositifs
Medical implants have revolutionised healthcare by improving quality of life through replacing missing structures, restoring function, and promoting tissue regeneration. However, implant-associated infections (IAIs) undermine these benefits, particularly in orthopaedics, otology, and odontology, leading to chronic issues and substantial healthcare costs. IAIs, exacerbated by biofilm formation and antimicrobial resistance, pose a significant public health challenge. The SHIELD doctoral network aims to advance our understanding of IAIs, from their multifactorial pathogenesis to the development of new antibacterial biomaterials, bridging the gap between basic research and practical applications. SHIELD is structured around three scientific pillars to advance IAI control strategies in orthopaedics, otology, and odontology: regenerative medicine, biomaterial science, and translational research models. These pillars drive research on therapeutic strategies, innovative biomaterials, and experimental proof-of-concept models. The network focuses on clinical studies, antimicrobial strategies for implants, and preclinical models to study IAI mechanisms. Our goal is to train 16 young researchers through an interdisciplinary and translational approach, combining basic research with preclinical and clinical testing. In collaboration with 27 partners from 11 countries, SHIELD brings together expertise from multiple disciplines to bridge the gap between research and real-world applications. By developing new antimicrobial solutions for implants and conducting bench-to-bedside research, SHIELD aims to improve infection management protocols and patient care, significantly advancing the field of infection control in medical devices.
| Amicoat AS | ? |
| Anthogyr SAS | 314 669 € |
| Ashland Specialties Ireland Ltd. | 341 087 € |
| Fundacion Publica Miguel Servet | 282 188 € |
| Goeteborgs Universitet | 973 890 € |
| KLINIKUM DER UNIVERSITAET REGENSBURG | 580 545 € |
| TECHNISCHE UNIVERSITAET DRESDEN | 290 272 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 348 738 € |
| The University of Birmingham | 348 738 € |
| Universita Degli Studi Di Torino | 281 755 € |
| Universitat Autonoma de Barcelona | 282 188 € |
| Universitetet I Oslo | 339 932 € |
| University College Dublin, National University of Ireland, Dublin | 341 087 € |
https://cordis.europa.eu/project/id/101226717
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Amicoat AS, Asker, Norvège.
